Skip to main content
PMC home page
The British Journal of Cancer. Supplement logoLink to The British Journal of Cancer. Supplement
. 1992 Dec;19:S2–S8.

Neuropharmacology of emesis in relation to clinical response.

B Costall 1, R J Naylor 1
PMCID: PMC2149641  PMID: 1467196

Abstract

5-HT3 receptor antagonists such as ondansetron, granisetron, ICS205-930 and zacopride are highly effective in the ferret, cat or dog to prevent emesis caused by cisplatin and other chemotherapeutic agents, and radiation treatment. The anti-emetic effects may be mediated centrally in the area postrema and associated structures of the emetic reflex such as the nucleus tractus solitarius, which have a very high density of 5-HT3 receptors. Additional sites of action may be found on the 5-HT3 receptors located on the vagus nerve or enteric neuronal elements in the gastro-intestinal tract. The precise site(s) and mechanism(s) of action of different cytotoxic treatments to induce emesis remains to be determined, but appears to involve a common action on a 5-HT3 system. The 5-HT3 receptor antagonists do not impair normal behaviour and, in particular, fail to affect the extrapyramidal motor system and do not cause sedation. Of potential benefit, the 5-HT3 receptor antagonists have an anxiolytic profile of action in rodent and primate models. The 5-HT3 receptor antagonists are revealed as an important group of drugs to prevent emesis induced by a wide range of cytotoxic treatments.

Full text

PDF
S2

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews P. L., Davis C. J., Bingham S., Davidson H. I., Hawthorn J., Maskell L. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol. 1990 Feb;68(2):325–345. doi: 10.1139/y90-047. [DOI] [PubMed] [Google Scholar]
  2. Andrews P. L., Hawthorn J. Evidence for an extra-abdominal site of action for the 5-HT3 receptor antagonist BRL24924 in the inhibition of radiation-evoked emesis in the ferret. Neuropharmacology. 1987 Sep;26(9):1367–1370. doi: 10.1016/0028-3908(87)90100-6. [DOI] [PubMed] [Google Scholar]
  3. BOGDANSKI D. F., WEISSBACH H., UDENFRIEND Pharmacological studies with the serotonin precursor, 5-hydroxytryptophan. J Pharmacol Exp Ther. 1958 Feb;122(2):182–194. [PubMed] [Google Scholar]
  4. BORISON H. L., WANG S. C. Physiology and pharmacology of vomiting. Pharmacol Rev. 1953 Jun;5(2):193–230. [PubMed] [Google Scholar]
  5. BRIZZEE K. R. Effect of localized brain stem lesions and supradiaphragmatic vagotomy on x-irradiation emesis in the monkey. Am J Physiol. 1956 Dec;187(3):567–570. doi: 10.1152/ajplegacy.1956.187.3.567. [DOI] [PubMed] [Google Scholar]
  6. Barnes J. M., Barnes N. M., Costall B., Naylor R. J., Tattersall F. D. Reserpine, para-chlorophenylalanine and fenfluramine antagonise cisplatin-induced emesis in the ferret. Neuropharmacology. 1988 Aug;27(8):783–790. doi: 10.1016/0028-3908(88)90092-5. [DOI] [PubMed] [Google Scholar]
  7. Barnes N. M., Costall B., Ironside J. W., Naylor R. J. Identification of 5-HT3 recognition sites in human brain tissue using [3H]zacopride. J Pharm Pharmacol. 1988 Sep;40(9):668–668. doi: 10.1111/j.2042-7158.1988.tb05338.x. [DOI] [PubMed] [Google Scholar]
  8. Bermudez J., Boyle E. A., Miner W. D., Sanger G. J. The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer. 1988 Nov;58(5):644–650. doi: 10.1038/bjc.1988.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bhargava K. P., Dixit K. S., Gupta Y. K. Enkephalin receptors in the emetic chemoreceptor trigger zone of the dog. Br J Pharmacol. 1981 Mar;72(3):471–475. doi: 10.1111/j.1476-5381.1981.tb10998.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Bonneterre J., Chevallier B., Metz R., Fargeot P., Pujade-Lauraine E., Spielmann M., Tubiana-Hulin M., Paes D., Bons J. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J Clin Oncol. 1990 Jun;8(6):1063–1069. doi: 10.1200/JCO.1990.8.6.1063. [DOI] [PubMed] [Google Scholar]
  11. Borison H. L., McCarthy L. E., Johnson J. R. High dorsal column cordotomy plus subdiaphragmatic vagotomy prevents acute ionizing radiation sickness in cats. Exp Neurol. 1987 Dec;98(3):645–658. doi: 10.1016/0014-4886(87)90272-x. [DOI] [PubMed] [Google Scholar]
  12. Bradley P. B., Engel G., Feniuk W., Fozard J. R., Humphrey P. P., Middlemiss D. N., Mylecharane E. J., Richardson B. P., Saxena P. R. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology. 1986 Jun;25(6):563–576. doi: 10.1016/0028-3908(86)90207-8. [DOI] [PubMed] [Google Scholar]
  13. CAHEN R. L. ON THE MECHANISM OF EMESIS INDUCED BY 5-HYDROXYTRYPTAMINE. Proc Soc Exp Biol Med. 1964 Jun;116:402–404. doi: 10.3181/00379727-116-29260. [DOI] [PubMed] [Google Scholar]
  14. CHINN H. I., WANG S. C. Locus of emetic action following irradiation. Proc Soc Exp Biol Med. 1954 Mar;85(3):472–474. doi: 10.3181/00379727-85-20922. [DOI] [PubMed] [Google Scholar]
  15. Costall B., Domeney A. M., Naylor R. J., Owera-Atepo J. B., Rudd J. A., Tattersall F. D. Fluphenazine, ICS 205-930 and dl-fenfluramine differentially antagonise drug-induced emesis in the ferret. Neuropharmacology. 1990 May;29(5):453–462. doi: 10.1016/0028-3908(90)90167-p. [DOI] [PubMed] [Google Scholar]
  16. Costall B., Domeney A. M., Naylor R. J., Tattersall F. D. 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology. 1986 Aug;25(8):959–961. doi: 10.1016/0028-3908(86)90030-4. [DOI] [PubMed] [Google Scholar]
  17. Costall B., Naylor R. J., Tyers M. B. The psychopharmacology of 5-HT3 receptors. Pharmacol Ther. 1990;47(2):181–202. doi: 10.1016/0163-7258(90)90086-h. [DOI] [PubMed] [Google Scholar]
  18. Craig D. A., Clarke D. E. Peristalsis evoked by 5-HT and renzapride: evidence for putative 5-HT4 receptor activation. Br J Pharmacol. 1991 Mar;102(3):563–564. doi: 10.1111/j.1476-5381.1991.tb12211.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Cubeddu L. X., Hoffmann I. S., Fuenmayor N. T., Finn A. L. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med. 1990 Mar 22;322(12):810–816. doi: 10.1056/NEJM199003223221204. [DOI] [PubMed] [Google Scholar]
  20. Eglen R. M., Swank S. R., Walsh L. K., Whiting R. L. Characterization of 5-HT3 and 'atypical' 5-HT receptors mediating guinea-pig ileal contractions in vitro. Br J Pharmacol. 1990 Nov;101(3):513–520. doi: 10.1111/j.1476-5381.1990.tb14113.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Elswood C. J., Bunce K. T., Humphrey P. P. Identification of putative 5-HT4 receptors in guinea-pig ascending colon. Eur J Pharmacol. 1991 Apr 17;196(2):149–155. doi: 10.1016/0014-2999(91)90421-l. [DOI] [PubMed] [Google Scholar]
  22. FELDBERG W., SHERWOOD S. L. Injections of drugs into the lateral ventricle of the cat. J Physiol. 1954 Jan;123(1):148–167. doi: 10.1113/jphysiol.1954.sp005040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Fetting J. H., McCarthy L. E., Borison H. L., Colvin M. Vomiting induced by cyclophosphamide and phosphoramide mustard in cats. Cancer Treat Rep. 1982 Aug;66(8):1625–1629. [PubMed] [Google Scholar]
  24. Fozard J. R., Mobarok ALI A. T. Blockade of neuronal tryptamine receptors by metoclopramide. Eur J Pharmacol. 1978 May 1;49(1):109–112. doi: 10.1016/0014-2999(78)90228-5. [DOI] [PubMed] [Google Scholar]
  25. Fozard J. R., Mwaluko G. M. Mechanism of the indirect sympathomimetic effect of 5-hydroxytrypt-amine on the isolated heart of the rabbit. Br J Pharmacol. 1976 May;57(1):115–125. doi: 10.1111/j.1476-5381.1976.tb07661.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Gordon J. C., Barefoot D. S., Sarbin N. S., Pinkus L. M. [3H]zacopride binding to 5-hydroxytryptamine3 sites on partially purified rabbit enteric neuronal membranes. J Pharmacol Exp Ther. 1989 Dec;251(3):962–968. [PubMed] [Google Scholar]
  27. Grunberg S. M., Akerley W. L., Krailo M. D., Johnson K. B., Baker C. R., Cariffe P. A. Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis. Cancer Invest. 1986;4(5):379–385. doi: 10.3109/07357908609017518. [DOI] [PubMed] [Google Scholar]
  28. Gylys J. A., Wright R. N., Nicolosi W. D., Buyniski J. P., Crenshaw R. R. BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties. J Pharmacol Exp Ther. 1988 Mar;244(3):830–837. [PubMed] [Google Scholar]
  29. HAYAMA T., OGURA Y. Site of emetic action of tetrodotoxin in dog. J Pharmacol Exp Ther. 1963 Jan;139:94–96. [PubMed] [Google Scholar]
  30. Hawthorn J., Cunningham D. Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret. Br J Cancer. 1990 Jan;61(1):56–60. doi: 10.1038/bjc.1990.12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Hawthorn J., Ostler K. J., Andrews P. L. The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret. Q J Exp Physiol. 1988 Jan;73(1):7–21. doi: 10.1113/expphysiol.1988.sp003124. [DOI] [PubMed] [Google Scholar]
  32. Higgins G. A., Kilpatrick G. J., Bunce K. T., Jones B. J., Tyers M. B. 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol. 1989 May;97(1):247–255. doi: 10.1111/j.1476-5381.1989.tb11948.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Kaasa S., Kvaløy S., Dicato M. A., Ries F., Huys J. V., Royer E., Carruthers L. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group. Eur J Cancer. 1990 Mar;26(3):311–314. doi: 10.1016/0277-5379(90)90227-k. [DOI] [PubMed] [Google Scholar]
  34. Kilpatrick G. J., Jones B. J., Tyers M. B. Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species. Eur J Pharmacol. 1989 Jan 10;159(2):157–164. doi: 10.1016/0014-2999(89)90700-0. [DOI] [PubMed] [Google Scholar]
  35. Kilpatrick G. J., Jones B. J., Tyers M. B. Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature. 1987 Dec 24;330(6150):746–748. doi: 10.1038/330746a0. [DOI] [PubMed] [Google Scholar]
  36. King G. L. Characterization of radiation-induced emesis in the ferret. Radiat Res. 1988 Jun;114(3):599–612. [PubMed] [Google Scholar]
  37. Kris M. G., Gralla R. J., Clark R. A., Tyson L. B. Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J Natl Cancer Inst. 1989 Jan 4;81(1):42–46. doi: 10.1093/jnci/81.1.42. [DOI] [PubMed] [Google Scholar]
  38. Kucharczyk J., Harding R. K. Regulatory peptides and the onset of nausea and vomiting. Can J Physiol Pharmacol. 1990 Feb;68(2):289–293. doi: 10.1139/y90-043. [DOI] [PubMed] [Google Scholar]
  39. Leslie R. A., Reynolds D. J., Andrews P. L., Grahame-Smith D. G., Davis C. J., Harvey J. M. Evidence for presynaptic 5-hydroxytryptamine3 recognition sites on vagal afferent terminals in the brainstem of the ferret. Neuroscience. 1990;38(3):667–673. doi: 10.1016/0306-4522(90)90060-h. [DOI] [PubMed] [Google Scholar]
  40. Lucot J. B. Blockade of 5-hydroxytryptamine3 receptors prevents cisplatin-induced but not motion- or xylazine-induced emesis in the cat. Pharmacol Biochem Behav. 1989 Jan;32(1):207–210. doi: 10.1016/0091-3057(89)90235-9. [DOI] [PubMed] [Google Scholar]
  41. Marty M., Pouillart P., Scholl S., Droz J. P., Azab M., Brion N., Pujade-Lauraine E., Paule B., Paes D., Bons J. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med. 1990 Mar 22;322(12):816–821. doi: 10.1056/NEJM199003223221205. [DOI] [PubMed] [Google Scholar]
  42. Miner W. D., Sanger G. J. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol. 1986 Jul;88(3):497–499. doi: 10.1111/j.1476-5381.1986.tb10228.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Miner W. D., Sanger G. J., Turner D. H. Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis. Br J Cancer. 1987 Aug;56(2):159–162. doi: 10.1038/bjc.1987.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Pinkus L. M., Sarbin N. S., Barefoot D. S., Gordon J. C. Association of [3H]zacopride with 5-HT3 binding sites. Eur J Pharmacol. 1989 Sep 22;168(3):355–362. doi: 10.1016/0014-2999(89)90797-8. [DOI] [PubMed] [Google Scholar]
  45. Pratt G. D., Bowery N. G., Kilpatrick G. J., Leslie R. A., Barnes N. M., Naylor R. J., Jones B. J., Nelson D. R., Palacids J. M., Slater P. Consensus meeting agrees distribution of 5-HT3 receptors in mammalian hindbrain. Trends Pharmacol Sci. 1990 Apr;11(4):135–137. doi: 10.1016/0165-6147(90)90058-g. [DOI] [PubMed] [Google Scholar]
  46. Reeves J. J., Bunce K. T., Humphrey P. P. Investigation into the 5-hydroxytryptamine receptor mediating smooth muscle relaxation in the rat oesophagus. Br J Pharmacol. 1991 May;103(1):1067–1072. doi: 10.1111/j.1476-5381.1991.tb12301.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Reynolds D. J., Leslie R. A., Grahame-Smith D. G., Harvey J. M. Localization of 5-HT3 receptor binding sites in human dorsal vagal complex. Eur J Pharmacol. 1989 Dec 12;174(1):127–130. doi: 10.1016/0014-2999(89)90884-4. [DOI] [PubMed] [Google Scholar]
  48. Sanger G. J., King F. D. From metoclopramide to selective gut motility stimulants and 5-HT3 receptor antagonists. Drug Des Deliv. 1988 Dec;3(4):273–295. [PubMed] [Google Scholar]
  49. Smith D. B., Newlands E. S., Spruyt O. W., Begent R. H., Rustin G. J., Mellor B., Bagshawe K. D. Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy. Br J Cancer. 1990 Feb;61(2):323–324. doi: 10.1038/bjc.1990.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Smith W. L., Alphin R. S., Jackson C. B., Sancilio L. F. The antiemetic profile of zacopride. J Pharm Pharmacol. 1989 Feb;41(2):101–105. doi: 10.1111/j.2042-7158.1989.tb06402.x. [DOI] [PubMed] [Google Scholar]
  51. Smith W. L., Callaham E. M., Alphin R. S. The emetic activity of centrally administered cisplatin in cats and its antagonism by zacopride. J Pharm Pharmacol. 1988 Feb;40(2):142–143. doi: 10.1111/j.2042-7158.1988.tb05202.x. [DOI] [PubMed] [Google Scholar]
  52. Stables R., Andrews P. L., Bailey H. E., Costall B., Gunning S. J., Hawthorn J., Naylor R. J., Tyers M. B. Antiemetic properties of the 5HT3-receptor antagonist, GR38032F. Cancer Treat Rev. 1987 Dec;14(3-4):333–336. doi: 10.1016/0305-7372(87)90026-0. [DOI] [PubMed] [Google Scholar]
  53. Sugiyama H., Hayama T., Yagasaki O. Emetic action of bacterial endotoxin in the cat. Proc Soc Exp Biol Med. 1966 Jan;121(1):278–281. doi: 10.3181/00379727-121-30758. [DOI] [PubMed] [Google Scholar]
  54. Vermorken J. B., Pinedo H. M. Gastrointestinal toxicity of cis-diamminedichloroplatinum (II). Neth J Med. 1982;25(8):275–279. [PubMed] [Google Scholar]

Articles from The British Journal of Cancer. Supplement are provided here courtesy of Cancer Research UK

RESOURCES